Nemokamas pristatymas nuo 29€

  • check 10 + milijonai knygų
  • check Naujienos (kiekvieną dieną)
  • check 1 + mln. klientų mus pasitiki
  • check Geros kainos % Nuolaidos
  • check Nemokamas pristatymas nuo 29 eur

Anxiolytics - Mike Briley,David Nutt

Anglų
2000-09-01
160,13 € 213,50 €

-25% su kodu BOOKS

Minkšti viršeliai Kieti viršeliai 213,50 €
Turime sandėlyje pas mūsų tiekėją

Pristatymas per 10-16 d.d.

30 dienų grąžinimo politika

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of ... Visas aprašymas

Jums taip pat gali patikti

Aprašymas

For over thirty years the benzodiazepines monopolised not only the anxiolytic market but also clinical and animal research in anxiety. Indeed many animal tests developed since the 1960s have been optimised for the benzodiazepines and some programmes have even screened candidates as potential anxiolytics on their benzodiazepine-like side-effects rather than their anxiolytic activity. With the realisation of the drawbacks of the benzodiazepines, namely their potential for tolerance and dependency, there has been a renewed interest in alternative anxiolytics both from existing drugs such as the tricyclic and monoamine oxidase antidepressants and from newer agents such as buspirone. In addition anxiety is no longer considered to be a unique entity but rather an umbrella term for a series of specific anxiety disorders such as panic disorder without or with agoraphobia, generalised anxiety disorder (GAD), specific phobias, social phobias and post-traumatic stress disorder (PTSD). These new clinical categories have opened another dimension in the therapy of anxiety requiring the optimisation of treatments for different syndromes. This book is a critical review of today's anxiolytics and those that may become the anxiolytics of tomorrow. What is clear is that currently there are few clinically satisfactory alternatives to the benzodiazepines for the treatment of acute anxiety. For chronic anxiety, it is generally agreed that benzodi azepines are not the treatment of first choice. The tricyclic and monoamine oxidase antidepressants, the serotonin reuptake inhibitors and buspirone offer better solutions for chronic anxiety but they are still far from being ideal.

Daugiau informacijos

Autorius Mike Briley, David Nutt
Leidėjas Springer Science & Business Media
Išleidimo metai 2000
Viršelio tipas Kieti viršeliai
EAN 9783764360320
Parašykite savo atsiliepimą
Jūs peržiūrėjote: Anxiolytics
Jūsų įvertinimas:

Goodreads Atsiliepimai

160,13 € 213,50 €